Dividends & Buybacks ·
At its Annual Meeting on June 11, 2026, Quince Therapeutics stockholders approved an amendment to the Certificate of…
QNCXIRulya Therapeutics Inc.
At its Annual Meeting on June 11, 2026, Quince Therapeutics stockholders approved an amendment to the Certificate of Incorporation to allow for a reverse stock split of common stock at a ratio ranging from 1-for-10 to 1-for-100, to be implemented at the board's discretion. Other approved items included the election of June Bray as a Class I director, the ratification of BDO USA, P.C. as the independent registered accounting firm for fiscal year 2026, and the advisory approval of executive compensation. The company operates in the biotechnology industry and develops therapeutic products.